MedPath

GALMED RESEARCH AND DEVELOPMENT LTD

🇮🇱Israel
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

8

Active:4
Completed:2

Trial Phases

3 Phases

Phase 1:5
Phase 2:2
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials

Phase 1
5 (62.5%)
Phase 2
2 (25.0%)
Phase 3
1 (12.5%)

A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis

Phase 2
Withdrawn
Conditions
Primary Sclerosing Cholangitis
Interventions
First Posted Date
2023-10-23
Last Posted Date
2025-06-12
Lead Sponsor
Galmed Research and Development, Ltd.
Target Recruit Count
24
Registration Number
NCT06095986
Locations
🇺🇸

The Sanyal Institute for Liver Disease & Metabolic Health at VCU, Richmond, Virginia, United States

Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment

First Posted Date
2020-07-21
Last Posted Date
2024-08-14
Lead Sponsor
Galmed Research and Development, Ltd.
Target Recruit Count
57
Registration Number
NCT04480827
Locations
🇺🇸

Division of Clinical Pharmacology, University of Miami, Miami, Florida, United States

🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

🇺🇸

Alliance for Multispecialty Research, Knoxville, Tennessee, United States

A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)

Phase 3
Suspended
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
First Posted Date
2019-09-26
Last Posted Date
2024-12-16
Lead Sponsor
Galmed Research and Development, Ltd.
Target Recruit Count
157
Registration Number
NCT04104321
Locations
🇺🇸

The Public Health Trust of Miami-Dade County, Florida, dba the Jackson Health System, Miami, Florida, United States

🇺🇸

Texas Clinical Research Institute, LLC, Arlington, Texas, United States

A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH

Phase 2
Completed
Conditions
Non-Alcoholic Steatohepatitis
Fatty Liver
Liver Diseases
Liver Fibroses
Interventions
First Posted Date
2014-10-31
Last Posted Date
2021-07-14
Lead Sponsor
Galmed Research and Development, Ltd.
Target Recruit Count
247
Registration Number
NCT02279524
Locations
🇺🇸

Profil Institue for Clinical Research Inc., Chula Vista, California, United States

🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

California Liver Research Institute, Pasadena, California, United States

and more 74 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.